Developing a personalized heterologous prime boost vaccination strategy for tumor therapy by Ramirez-Valdez, RA

Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression by Ramirez-Valdez, RA, Baharom, F, Khalilnezhad, A, Fussell, SC, Hermans, DJ, Schrager, AM, Tobin, KKS, Lynn, GM, Khalilnezhad, S, Ginhoux, F, Van den Eynde, BJ, Leung, CSK, Ishizuka, AS, Seder, RA

Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy by McAuliffe, J, Chan, HF, Noblecourt, L, Ramirez-Valdez, RA, Pereira-Almeida, V, Zhou, Y, Pollock, E, Cappuccini, F, Redchenko, I, Hill, AV, Leung, CSK, Van den Eynde, BJ

Peptide–TLR-7/8a conjugate vaccines chemically programmed for nanoparticle self-assembly enhance CD8 T-cell immunity to tumor antigens by Lynn, GM, Sedlik, C, Baharom, F, Zhu, Y, Ramirez-Valdez, RA, Coble, VL, Tobin, K, Nichols, SR, Itzkowitz, Y, Zaidi, N, Gammon, JM, Blobel, NJ, Denizeau, J, de la Rochere, P, Francica, BJ, Decker, B, Maciejewski, M, Cheung, J, Yamane, H, Smelkinson, MG, Francica, JR, Laga, R, Bernstock, JD, Seymour, LW, Drake, CG, Jewell, CM, Lantz, O, Piaggio, E, Ishizuka, AS, Seder, RA